LakeShore Capex To Operating Cash Flow from 2010 to 2026

LSBCF Stock   0.06  0.02  19.50%   
LakeShore Biopharma's Capex To Operating Cash Flow is decreasing over the last several years with stable swings. Capex To Operating Cash Flow is predicted to flatten to -0.14. During the period from 2010 to 2026 LakeShore Biopharma Co Capex To Operating Cash Flow regressed destribution of quarterly values had mean deviationof  53.94 and mean square error of  14,544. View All Fundamentals
 
Capex To Operating Cash Flow  
First Reported
2010-12-31
Previous Quarter
(0.13)
Current Value
(0.14)
Quarterly Volatility
118.14589861
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check LakeShore Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LakeShore Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 38.4 M, Interest Expense of 27.1 M or Selling General Administrative of 134.5 M, as well as many indicators such as Price To Sales Ratio of 3.38, Dividend Yield of 0.0 or PTB Ratio of 4.16. LakeShore financial statements analysis is a perfect complement when working with LakeShore Biopharma Valuation or Volatility modules.
  
Build AI portfolio with LakeShore Stock
Check out the analysis of LakeShore Biopharma Correlation against competitors.
The Capex To Operating Cash Flow trend for LakeShore Biopharma Co offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether LakeShore Biopharma is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest LakeShore Biopharma's Capex To Operating Cash Flow Growth Pattern

Below is the plot of the Capex To Operating Cash Flow of LakeShore Biopharma Co over the last few years. It is LakeShore Biopharma's Capex To Operating Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LakeShore Biopharma's overall financial position and show how it may be relating to other accounts over time.
Capex To Operating Cash Flow10 Years Trend
Pretty Stable
   Capex To Operating Cash Flow   
       Timeline  

LakeShore Capex To Operating Cash Flow Regression Statistics

Arithmetic Mean(29.00)
Coefficient Of Variation(407.37)
Mean Deviation53.94
Median(0.43)
Standard Deviation118.15
Sample Variance13,958
Range487
R-Value(0.15)
Mean Square Error14,544
R-Squared0.02
Significance0.56
Slope(3.56)
Total Sum of Squares223,335

LakeShore Capex To Operating Cash Flow History

2026 -0.14
2025 -0.13
2023 -0.15
2022 -0.31
2021 -487.48

About LakeShore Biopharma Financial Statements

LakeShore Biopharma stakeholders use historical fundamental indicators, such as LakeShore Biopharma's Capex To Operating Cash Flow, to determine how well the company is positioned to perform in the future. Although LakeShore Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in LakeShore Biopharma's assets and liabilities are reflected in the revenues and expenses on LakeShore Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in LakeShore Biopharma Co. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Operating Cash Flow(0.13)(0.14)

Currently Active Assets on Macroaxis

When determining whether LakeShore Biopharma is a strong investment it is important to analyze LakeShore Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact LakeShore Biopharma's future performance. For an informed investment choice regarding LakeShore Stock, refer to the following important reports:
Check out the analysis of LakeShore Biopharma Correlation against competitors.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Can Biotechnology industry sustain growth momentum? Does LakeShore have expansion opportunities? Factors like these will boost the valuation of LakeShore Biopharma. Expected growth trajectory for LakeShore significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating LakeShore Biopharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding LakeShore Biopharma requires distinguishing between market price and book value, where the latter reflects LakeShore's accounting equity. The concept of intrinsic value - what LakeShore Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push LakeShore Biopharma's price substantially above or below its fundamental value.
Understanding that LakeShore Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether LakeShore Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, LakeShore Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.